Robecosam AG grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 17.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 234,880 shares of the biopharmaceutical company’s stock after purchasing an additional 35,367 shares during the period. Robecosam AG’s holdings in Gilead Sciences were worth $15,756,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Gilead Sciences during the 1st quarter worth about $2,305,000. Centric Wealth Management purchased a new position in shares of Gilead Sciences during the 2nd quarter worth about $216,000. Regentatlantic Capital LLC lifted its holdings in shares of Gilead Sciences by 26.4% during the 1st quarter. Regentatlantic Capital LLC now owns 42,596 shares of the biopharmaceutical company’s stock worth $2,769,000 after acquiring an additional 8,886 shares during the period. Private Trust Co. NA purchased a new position in shares of Gilead Sciences during the 2nd quarter worth about $203,000. Finally, PICTET BANK & TRUST Ltd purchased a new position in shares of Gilead Sciences during the 1st quarter worth about $260,000. 78.87% of the stock is currently owned by institutional investors.
In related news, EVP Brett A. Pletcher sold 7,200 shares of the firm’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $65.07, for a total value of $468,504.00. Following the transaction, the executive vice president now owns 34,398 shares in the company, valued at $2,238,277.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Brett A. Pletcher sold 5,816 shares of the firm’s stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $68.75, for a total transaction of $399,850.00. Following the completion of the transaction, the executive vice president now owns 27,198 shares in the company, valued at approximately $1,869,862.50. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.
NASDAQ GILD traded up $0.59 during mid-day trading on Tuesday, hitting $64.57. The company’s stock had a trading volume of 247,137 shares, compared to its average volume of 6,310,354. Gilead Sciences, Inc. has a 52-week low of $60.32 and a 52-week high of $79.61. The company has a fifty day moving average price of $66.52. The company has a quick ratio of 3.67, a current ratio of 3.76 and a debt-to-equity ratio of 1.13. The stock has a market cap of $82.62 billion, a price-to-earnings ratio of 10.50, a P/E/G ratio of 3.10 and a beta of 1.16.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.68 by $0.14. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. The firm had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.54 billion. During the same quarter last year, the firm posted $1.91 earnings per share. Gilead Sciences’s revenue for the quarter was down 2.8% compared to the same quarter last year. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 6.65 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be issued a $0.63 dividend. The ex-dividend date is Thursday, September 12th. This represents a $2.52 annualized dividend and a yield of 3.90%. Gilead Sciences’s payout ratio is 40.98%.
Several research analysts have recently weighed in on GILD shares. Citigroup set a $78.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, July 31st. Wells Fargo & Co upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $68.00 to $88.00 in a report on Monday, July 15th. Maxim Group set a $84.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, July 31st. Oppenheimer set a $85.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Friday, July 12th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating and set a $85.00 price objective on shares of Gilead Sciences in a report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the company’s stock. Gilead Sciences presently has a consensus rating of “Buy” and a consensus target price of $82.29.
Gilead Sciences Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
See Also: Discount Rate
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.